News

The 3 Best Leveraged ETFs for April 2024

  • While there are many ways to gamble in the equities sector, targeting the best leveraged ETFs for April could be a recipe for success. To be sure, you're going to have to accept a heightened risk profile.
    04/02/2024

Top Performing Leveraged/Inverse ETFs: 03/03/2024

  • These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
    03/05/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Direxion Daily S&P Biotech Bull 3X Shares (LABU) is 104 and it was updated on 2024-04-12 13:00:32.

Currently Direxion Daily S&P Biotech Bull 3X Shares (LABU) is in undervalued.

News
    
News

4 Best Inverse/Leveraged ETF Areas of Last Week

  • Wall Street offered mixed performance last week.
    Mon, Mar. 04, 2024

LABU: A Really Bad Drift

  • Leveraged ETFs have a non-linear, unpredictable behavior. Here is a drift dashboard with 22 leveraged ETFs. Direxion Daily S&P Biotech Bull 3X Shares ETF is the worst. LABU is an instrument for seasoned traders with planned entry and exit signals. Without a tested strategy and daily monitoring, it is an accident waiting to happen.
    Sun, Mar. 03, 2024

5 Best-Performing Leveraged ETFs of February

  • U.S. stocks rallied in February, with the S&P 500 and the Nasdaq Composite Index recording the best month in nearly a decade.
    Fri, Mar. 01, 2024

Early IPO Activity Could Spell Bullishness for Biotech Industry

  • Since the end of October 2023, the S&P 500 Biotechnology Select Industry Index jumped over 30%. It could maintain its upward trajectory given the early IPO activity in 2024 thus far.
    Fri, Jan. 26, 2024

5 Leveraged ETFs That Are Up More Than 50% in December

  • The demand for leveraged ETFs have increased as investors seek to register big gains in a short span.
    Wed, Dec. 27, 2023
SEC Filings
SEC Filings
More Headlines
News

Top Performing Leveraged/Inverse ETFs: 12/17/2023

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 12/19/2023

Best Inverse/Leveraged ETFs of Last Week

  • Wall Street was upbeat last week. Stocks closed their longest winning streak since 2017.
  • 12/18/2023

LABU: Buy As The Biotech Sector Starts A New Bull Market (Technical Analysis)

  • Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology Select Industry Index. I believe LABU has strong momentum and is outperforming the broad market, making it a favorable investment.
  • 12/16/2023

LABU: Tool For Swing Traders

  • The Direxion Daily S&P Biotech Bull and Bear 3X Shares (LABU) provides 3x daily exposure to a biotechnology index. Levered ETFs like LABU are designed for short-term trading and may suffer tracking errors from positive convexity and volatility decay. LABU can be used as a swing trading tool for experienced traders, taking advantage of positive convexity and macro tailwinds in biotech stocks.
  • 12/10/2023

Top Performing Leveraged/Inverse ETFs: 12/03/2023

  • These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 12/05/2023

Top Performing Leveraged/Inverse ETFs: 11/19/2023

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 11/21/2023

Best Inverse/Leveraged ETFs of Last Week

  • Wall Street was upbeat last week. The reason behind the market rally was cooling inflation.
  • 11/21/2023

Top Performing Leveraged/Inverse ETFs: 11/05/2023

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 11/07/2023

Breakouts Everywhere As Buffett Moves To Record High $157 Billion Cash

  • Warren Buffett's Berkshire Hathaway has reached record-high levels of cash, with $157 billion on hand, exceeding Disney's market capitalization. The last time Buffett held record cash levels was in late 2021, ahead of the 2022 market correction. Similar patterns are observed between 2018 and 2023, the only two years when the Fed hit multi-year high Fed funds rates while conducting the largest QT balance sheet reduction in history.
  • 11/06/2023

LABU And LABD: Another Attractive Double-Short Pairs Trade

  • Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode over time due to their higher beta and inability to stay correlated over longer timeframes. The performance of the couple is dependent on the behavior of the underlying, with the short couple expected to lose value during strong trends.
  • 09/29/2023

LABU: A Levered ETF Doomed From The Start

  • The Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) is a high-risk, leveraged ETF that aims to yield three times the performance of the S&P Biotechnology Select Industry Index. The biotech sector is known for its volatility, which can significantly impact the performance of LABU. Trading LABU is challenging due to the unpredictable nature of the biotech sector and the path dependence of leveraged ETFs. Investors should use caution and consider alternative investment options.
  • 08/20/2023

10 Most-Heavily Traded ETFs of the Last Three Months

  • High trading volume indicates high liquidity, which is a key characteristic of ETFs.
  • 07/10/2023

LABU: 2 Requirements For Making Money In This Leveraged Biotech Fund

  • LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU can work for medium term returns if two requirements are met.
  • 05/30/2023

Top Performing Leveraged/Inverse ETFs: 05/07/2023

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 05/10/2023

5 Leveraged/Inverse ETFs That Gained Double Digits in April

  • The month of April was marked by huge volatility. Though recession fears continued to weigh on investors sentiment, cooling inflation and better-than-expected earnings drove the stocks higher.
  • 05/02/2023

5 Best Inverse/Leveraged ETFs of Last Week

  • Wall Street offered a flat performance last week.
  • 04/25/2023

Leveraged Biotech ETFs: Hold LABU, Sell LABD

  • SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, the 3X leveraged Biotech ETF, is rated as a HOLD.
  • 04/19/2023

Want Diversified Upside in Biotechnology? Check out LABU

  • Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the one-day performance of the SPDR S&P 500 Biotech ETF (NYSE: XBI).
  • 03/22/2023

LABU: Leveraged Biotech ETF Review

  • Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap and small-cap biopharma.
  • 01/31/2023

Top Performing Leveraged/Inverse ETFs: 12/04/2022

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 12/07/2022

Best Inverse/Leveraged ETFs of Last Week

  • Last week was marked with record Cyber Monday online shopping, Fed cues of slower rate hike and upbeat U.S. jobs data.
  • 12/05/2022

LABU: Opportunities For Gains Exist If Bought And Sold At Correct Price

  • LABU is more volatile than unleveraged funds, due to its 3-times investments in the derivatives of stocks listed in its benchmark index. During the past 4 months, biotechnology stocks performed quite well, and this bull run has come during a period when the overall market performed poorly.
  • 10/28/2022

10 Most-Heavily Traded ETFs of Third Quarter 2022

  • The ETF industry is seeing explosive growth, piling up huge assets amid the stock market turmoil. This has resulted in enough liquidity in the ETF world, with most ETFs trading at extremely higher volumes.
  • 10/05/2022

Top Performing Leveraged/Inverse ETFs: 09/11/2022

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 09/13/2022

Biotech Bounces in August as M&A Activity Increases

  • The biotech sector deflated, as most sectors did, in the first half of 2022. However, the sector is in the midst of a comeback as mergers and acquisitions rise, signaling increased activity.
  • 08/22/2022

LABU Continues In Uptrend (Technical Analysis)

  • During July, LABU traded in a narrow range. In August, its uptrend has resumed. We expect that LABU's uptrend has a long way to go.
  • 08/12/2022

Top Performing Leveraged/Inverse ETFs: 08/07/2022

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 08/09/2022

Best Inverse/Leveraged ETFs of Last Week

  • Wall Street was moderate last week. oil prices too faded lately.
  • 08/08/2022

LABU And The Biotechs Look Ready To Outperform (Technical Analysis)

  • I believe small- and mid-cap biotech bottomed in May through June and has outperformed the broader market since then. Biotech continues to show strong relative outperformance versus the market and most sectors/industries.
  • 08/05/2022

Biotech Sector Is Garnering Interest From Investors Again

  • The biotech sector has been rallying as of late, evidenced by the S&P 500 Biotechnology Index up close to 9% within the past month. Of course, as we've seen so far in 2022, rallies are difficult to sustain given the market uncertainty.
  • 07/14/2022

Top Performing Leveraged/Inverse ETFs: 07/10/2022

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 07/12/2022

Leveraged Biotech ETFs: Buy LABU, Sell LABD

  • Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%.
  • 07/08/2022

Top Performing Leveraged/Inverse ETFs: 06/26/2022

  • Top Performing Levered/Inverse ETFs Last Week These were last week's top-performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
  • 06/29/2022

S&P 500's Second-Best Week in 2022: Best Leveraged ETFs

  • U.S. stocks saw a massive jump on the final trading session of last week, making the week successful one.
  • 06/27/2022

LABU: This 3X Leveraged Bull ETF Fails To Raise Any Optimism

  • Since my last coverage in the previous quarter, LABU has been on a free fall for the past 12 weeks and also recorded a huge loss over the past 6. 3X funds like LABU have the highest expense ratio and  extreme levels of volatility.
  • 06/23/2022

LABU: A 3X Leveraged ETF Best Avoided

  • LABU: A 3X Leveraged ETF Best Avoided
  • 03/31/2022

CURE: One Of The Best Performing 3X Shares ETF

  • CURE: One Of The Best Performing 3X Shares ETF
  • 03/24/2022

3 Leveraged ETF Stocks to Buy During This Extreme Uncertainty

  • Here are 3 stocks to buy on dips from scary geopolitical risks from Russia. These leveraged ETFs move extremely fast so bring your Dramamine.
  • 02/22/2022

Taking On Volatility With Geared ETFs

  • Direxion's Dave Mazza is seeing many traders using inverse and leveraged ETFs in the recent market movement.
  • 02/08/2022

LABU - A Compelling Biotech Trade

  • LABU, a triple ETF (3x) from Direxion Funds, tracks the S&P Biotechnology Select Industry Index.
  • 01/26/2022

3 Biotech Stocks to Buy That Are Under Severe Pressure

  • The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.
  • 01/13/2022

LABU: Now Best Near-Term Cap Gain Among Leveraged-Long ETFs Say Market-Maker Hedging Deals

  • MMs “fill” Institutional huge Block-Trades by borrowing otherwise unavailable shares, sell short, hedge the short risk, ultimately cover shorts in accommodative market periods. Short-risk hedge-sellers engineer their profitable postures using high-leverage derivative securities and arbitrage skills not typically available to the investing public.
  • 01/05/2022

5 Best Leveraged ETFs of Last Week

  • The S&P 500 hit to record close last week, as investors gained optimism from some of President Joe Biden's encouraging announcements regarding booster shots and testing kits.
  • 12/27/2021

5 Best Inverse/Leveraged ETF Areas of Last Week

  • Wall Street was downbeat last week with all notable U.S. indexes being in the red. Rising inflation, hawkish Fed and fast-spreading Omicron variant of COVID-19 led to this bloodbath.
  • 12/20/2021

Omicron Variant Is Boosting This Leveraged Biotech ETF

  • The Omicron variant re-asserted the strength of biotech equities, making the Direxion Daily S&P Biotech Bull 3x Shares (LABU) an option for traders. As investors turned up the risk dial, COVID-19 cases ticked up towards the end of the year, and now with the new variant, they can provide an attractive option for a short-term [.
  • 12/15/2021

Best Leveraged ETF Areas of Last Week

  • Wall Street was at the record high last week due to upbeat corporate earnings, strong jobs data and Pfizer's pill study.
  • 11/08/2021

LABU Provides Leveraged Access For Risk-Taking Investors

  • LABU Provides Leveraged Access For Risk-Taking Investors
  • 09/27/2021

ETF/ETN Breakouts Week 39 - September 2021: Short-Term Funds To Give You An Edge

  • This is the first public release of the weekly ETF/ETN forecast article, highlighting some strong sectors, index funds and commodities for your consideration. This report goes out weekly with live daily updates for members and may continue monthly for other readers of my articles.
  • 09/26/2021

7 Best Leveraged ETF Areas of Last Week

  • Wall Street was upbeat last week. News of zero new cases in China, U.S. FDA's full approval of Pfizer-BioNTech Covid-19 vaccine and no new flare-up in taper talks led to the gains.
  • 08/30/2021

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

  • Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
  • 08/26/2021

5 Best Inverse/Leveraged ETF Areas of Last Week

  • Last week was upbeat for Wall Street. Stocks basically ignored myriad of concerns including inflationary pressures and rising Delta variant of COVID-19 cases.
  • 08/09/2021

ARK: Cathie Wood And The Exquisite Art Of Tail Gunning

  • ARK Active ETFs are worth the management fee. Structured Lookback is introduced.
  • 06/14/2021

5 Best Leveraged ETFs of Last Week

  • We highlight a few leveraged ETF areas that won last week.
  • 06/14/2021

A Biotech ETF For Aggressive, Risk-Tolerant Investors

  • The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.
  • 06/08/2021

Best Leveraged ETF Areas of Last Week

  • Last week was slightly downbeat for Wall Street on talks of a capital gain tax hike.
  • 04/26/2021

Biotech Innovations Remain At Forefront

  • The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.
  • 04/16/2021

Moving Beyond COVID In Biopharma

  • Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.
  • 04/15/2021

These 3 Popular ETFs Are Geared Toward Tactical Plays

  • Direxion's weekly ETF fund flows could shed light on what traders are thinking. The top three point to interest in long-term bond prices, biotech strength, and semiconductor weakness.
  • 04/14/2021

Biden's Infrastructure Can Put These 2 Leveraged Funds in Play

  • U.S. president Joe Biden's infrastructure plan is opening up ETF trading possibilities from multiple angles. One way is playing its healthcare component via funds like the Direxion Daily Healthcare Bull 3X ETF (CURE) and the Direxion Daily S&P Biotech Bull 3X ETF (LABU).
  • 04/09/2021

6 Top Leveraged ETF Areas of Last Week

  • The S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 were all on an uptrend last week.
  • 03/15/2021

Leveraged ETFs In the Pink After 1 Year of Pandemic

  • Investors flocked to leveraged ETFs to cash in on the opportunity offered by an improving economy and a rising stock market.
  • 03/15/2021

6 Top Leveraged Areas of Last Week

  • The S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 were all on an uptrend last week.
  • 03/15/2021

6 Leveraged ETF Areas Up At Least 20% Last Week

  • Solid corporate earnings and expectations of a fat stimulus by U.S. President Joe Biden's administration have renewed the appeal for the riskier assets last week.
  • 02/08/2021

Up Over 100% in 2020 and 15% in 2021, ‘LABU' Isn't Holding Back

  • The biotechnology industry isn't backing down, with ETFs like the Direxion Daily S&P Biotech Bull 3x Shares (LABU) gaining over 15% to start the new year. More strength could be ahead as the global economy continues to battle with the Covid-19 pandemic.
  • 01/12/2021

6 Top-Performing Leveraged ETFs of Last Week

  • The S&P 500, the Nasdaq-100 and the Dow Jones gained about 3.6%, 5.9% and 3.4%, respectively, last week.
  • 01/11/2021

5 Best-Performing Leveraged ETFs of December

  • The month of December has been kind for the stock market with the major indices enjoying a historic rally despite the surge in coronavirus cases.
  • 12/29/2020

5 Best-Performing Leveraged ETFs of Fourth Quarter

  • We highlight some leveraged ETFs that gained more than 85% over the past three months.
  • 12/23/2020

3 Direxion ETFs Top List of Best Leveraged Performers

  • Traders understand that when you add leverage to the mix, the results can be explosive gains, but on the flip side, it could be losses and a blown trading account. Yahoo Finance focused on top leveraged ETF performers and three of the funds featured Direxion Investments products.
  • 12/22/2020

10 Best Performing Leveraged ETFs of 2020

  • This year has witnessed historic twists and turns with the largest bull market turning into a bear market in March on the coronavirus outbreak, and then marking the fastest-ever recovery.
  • 12/17/2020

SPXU Enters Positive Drift Regime

  • Leveraged ETFs sometimes have an unpredictable behavior. We illustrate our point with 22 ETFs tracking various indexes.
  • 09/02/2020

We Skipped The 3x Fangdango

  • Price movement is best explained by finite state theory as opposed to continuous time. These strategies are best suited for 401(k) accounts where there are no tax or record keeping issues.
  • 08/28/2020

Adjusting Strategies For Underlying Market Conditions

  • Specter/FF5 has powerful trend detection capabilities, facilitating automatic strategy adjustment. Don't play monkey see, monkey do with an algorithm you wrote.
  • 07/20/2020

SPXU: The Decay Has Worsened As Expected

  • Leveraged ETFs sometimes have an unpredictable behavior. We illustrate our point with 22 ETFs tracking various indexes. Then we focus on the behavior of SPXU.
  • 07/02/2020

Best Leveraged/Inverse ETFs of June

  • Investors rushed to leveraged or inverse leveraged ETFs in June to increase returns on quick market turns in a short span.
  • 06/29/2020

The Reopening Killed The V-Shaped Recovery

  • This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
  • 06/29/2020

V&M Premium Portfolio: 2020 Mid-Year Report Card Through Week 26

  • The Premium Portfolio is up +14.43% YTD, while the benchmark S&P 500 Index is down -6.86% through June 26th. The Premium Portfolio has beaten the S&P 500 every
  • 06/29/2020

Leveraged ETFs That More Than Doubled in Q2

  • We highlighted some leveraged equity ETFs that piled up more than 100% returns in the second quarter.
  • 06/26/2020

Leveraged ETFs That Have Gained More Than 80% at Halfway Q2

  • After a brutal first quarter, U.S. stocks strongly rebounded on an unprecedented fiscal and monetary stimulus, progress in the development of a coronavirus vaccine or treatment as well as optimism over the reopening of the economy.
  • 05/20/2020

Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert

  • Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
  • 05/18/2020

6 Leveraged ETFs Up At Least 25% Last Week

  • Oil, tech and biotech caused a rally in the leveraged ETF space last week.
  • 05/11/2020

Stocks surge as more states move to reopen amid coronavirus

  • JP Morgan Private Bank Head of Cross-Asset Thematic Strategy Anastasia Amoroso joins Yahoo Finance’s Seana Smith to discuss the latest market action as more states move to reopen their economies in the wake of the coronavirus.
  • 05/05/2020

USO, UCO, LABU and ITB among weekly ETF movers

  • Gainers: Direxion Homebuild & Suppliers Bull 3X (NYSEARCA:NAIL) +32.00%.Direxion S&P Biotech Bear 3X (NYSEARCA:LABD) +19.7%.Latin America Bull 3X Direxion (NYSEARCA:LBJ) +18.7%.Microsectors U.
  • 05/01/2020

Leveraged ETFs That More Than Doubled in April

  • U.S. stocks came back roaring in April buoyed by unprecedented fiscal and monetary stimulus, progress in the development of a coronavirus vaccine or treatment as well as optimism over the reopening of the economy.
  • 05/01/2020

Top Leveraged ETFs of Last Week

  • Last week was all about ebbs and flows in oil prices that led Wall Street to snap the weekly winning streak.
  • 04/27/2020

Top Leveraged ETFs of Last Week

  • Last week was all about ebbs and flows in oil prices that led Wall Street to snap the weekly winning streak.
  • 04/27/2020

5 Best Leveraged ETF Areas of Last Week

  • If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
  • 04/20/2020

USO, OIL, TQQQ and SQQQ among weekly ETF movers

  • Gainers: DB Crude Oil -2X ETN Powershares (NYSEARCA:DTO) +81.4%.BMO Rex Microsectors Fang Index 3X Leveraged Ex (NYSEARCA:FNGU) +35.0%.Direxion S&P Biotech Bull 3X (NYSEARCA:LABU) +30.2%.Ultrashor
  • 04/18/2020

Week 16 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Revealing more about the Momentum Gauge model in a new section to help you use the best types of trades for the best returns during different cycles. Two sample
  • 04/13/2020

Amarin Corportion Plc: Now Compelling On Ex-U.S. Opportunity And Potential Barriers To Generic Competition

  • A U.S. District Court ruling found that Amarin’s patents for Vascepa were invalid due to obviousness; shares dropped 71%. Amarin will appeal; Some believe the d
  • 04/06/2020

Week 15 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Revealing more about the Momentum Gauge model in a new section to help you use the best types of trades for the best returns during different cycles. Two sample
  • 04/04/2020

The Worst Decay In SPXU's History

  • Leveraged ETFs sometimes have an unpredictable behavior. We illustrate our point with 20+ ETFs in various asset classes and stock indexes. Then we focus on the
  • 04/03/2020

Week 14 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 14 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +11.10% YTD compared to the S&P 500 -2
  • 03/28/2020

Week 13 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 13 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +14.16% YTD compared to the S&P 500 -2
  • 03/21/2020

Week 12 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 12 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +11.60% YTD compared to the S&P 500 -1
  • 03/15/2020

Crisis Trading - 10 Buying The Dip Ideas

  • When the going gets tough, the tough go shopping. Especially when the tough are mainly in CASH!!! Here's 10 Blue Chip Trade Ideas we are picking up this morning
  • 03/12/2020

Leveraged ETFs Decays: Warning Signal For SPXU

  • Why do leveraged ETFs drift? The best and the worst drifts. A warning signal for SPXU.
  • 03/10/2020

Week 11 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Four new Breakout Stocks for Week 11 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +37.51% YTD compared to the S&P 500 -8.0
  • 03/09/2020

Week 10 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • One sample Breakout Stocks for Week 10 with better-than-10% short-term upside potential and one sample Dow stock. The MDA Breakout portfolio is up +41.50% YTD c
  • 03/02/2020

TECL: Beware Extreme Liquidity, Concentration Risk

  • Large technology companies like Apple and Microsoft seem to be in a typical end-of-bubble blow-off top speculative price pattern. This has caused 3X leveraged t
  • 02/24/2020

Week 9 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • One sample Breakout Stocks for Week 9 with better-than-10% short-term upside potential and one sample Dow 30 stock pick. The MDA Breakout portfolio is up +36.11
  • 02/24/2020

The 10 Best Index Funds to Buy and Hold

  • The 10 best index funds are a mix of buy-and-hold ETFs that will serve you for decades, as well as a couple tactical trading tools.
  • 02/24/2020

Week 8 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Four new Breakout Stocks for Week 8 with better-than-10% short-term upside potential. The MDA Breakout portfolio is up +31.69% YTD compared to the S&P 500 up 4.
  • 02/17/2020

Will These Tech Stock Valuations Last?

  • Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to
  • 02/13/2020

Simplex Trading LLC Reduces Stock Holdings in Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU)

  • Simplex Trading LLC trimmed its holdings in shares of Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) by 95.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 600 shares of the company’s stock after selling 11,309 shares during the […]
  • 02/11/2020

3 Leveraged Healthcare ETFs Soaring This Month

  • Here are some geared healthcare ETFs that are enjoying fabulous February and may have more in store over the next couple of weeks.
  • 02/11/2020

3 Leveraged Healthcare ETFs Soaring This Month

  • The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidemic. Predictably, the coronavirus outbreak is slamming an array of asset classes, but it's also providing a predictable lift to some healthcare stocks and the related exchange-traded funds. The “Wuhan virus” is also providing an ideal opportunity for active traders to capitalize on opportunities with leveraged healthcare ETFs. What follows are some geared healthcare ETFs that are enjoying fabulous February's and may have more in store over the next couple of weeks. Direxion Daily S&P Biotech Bull 3X Shares (LABU) Speculation is swirling that some smaller biotechnology companies could be somewhat close to getting coronavirus treatments to market (close means several months away) and that's lifting the Direxion Daily S&P Biotech … Full story available on Benzinga.com
  • 02/10/2020

Should Investors Avoid U.S. Healthcare Stocks In An Election Year?

  • US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. The US healthcare sector traded at a pric
  • 02/10/2020

Week 7 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 7 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
  • 02/10/2020

VXX, UVXY and TVIX among weekly ETF movers

  • Gainers: Direxion S&P Biotech Bull 3X (NYSEARCA:LABU) +21%.Ultrapro Biotechnology Proshares (NASDAQ:UBIO) +21%.BMO Rex Microsectors Fang Index 3X Leveraged Ex (NYSEARCA:FNGU) +21%.Direxion South K
  • 02/07/2020

Leveraged ETFs: Drift Dashboard

  • Why do leveraged ETFs drift? Our drift watch list. The best and the worst drifts. Pros and cons of hedging with SPXU.
  • 02/04/2020

Week 6 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 4 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
  • 02/02/2020

Week 5 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 4 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
  • 01/25/2020

Week 4 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 4 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
  • 01/18/2020

EQRx's Challenge, And My Challenge To Them

  • EQRx's plan is apparently to come up with new competing pharmaceuticals in existing categories and sell them for lower prices than the patented ones. Insurance
  • 01/16/2020

Week 3 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

  • Two sample Breakout Stocks for Week 3 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
  • 01/11/2020

Biotech Bonanza: 2020 Outlook In An Election Year

  • Biotechs closed out 2019 on a strong note, with the fourth quarter providing the longest sustained rally of the entire year. Favorable regulatory shifting, a ti
  • 01/08/2020

5 Top-Performing Leveraged ETFs of November

  • Inside the best five best leveraged ETFs of November.
  • 12/02/2019

Leveraged ETFs That Are Up 25% Plus at Halfway Q4

  • We have highlighted a few leveraged equity ETFs that have piled up more than 25% returns so far in the fourth quarter and could continue to be investors' darlings.
  • 11/20/2019

Best Leveraged ETF Areas of Last Week

  • These leveraged ETFs posted solid gains last week.
  • 11/04/2019

Sell on the Pop Prospects: September 18 Edition

  • Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to be in a downtrend based on the fact that its 50-day moving average is below its 200-day moving average, which are popular indicators for gauging long-term and medium-term trends, respectively. Second, each of these ETFs is also trading above its 20-day moving average, thereby offering a near-term 'sell on the pop' opportunity given the longer-term downtrend at hand. Note that this prospects list also features a liquidity screen by excluding ETFs with average trading volumes below the one million shares mark. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
  • 09/18/2019

Sell on the Pop Prospects: July 24 Edition

  • Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to be in a downtrend based on the fact that its 50-day moving average is below its 200-day moving average, which are popular indicators for gauging long-term and medium-term trends, respectively. Second, each of these ETFs is also trading above its 20-day moving average, thereby offering a near-term 'sell on the pop' opportunity given the longer-term downtrend at hand. Note that this prospects list also features a liquidity screen by excluding ETFs with average trading volumes below the one million shares mark. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
  • 07/24/2019

BIB Versus LABU: Comparing Leveraged Biotech ETFs

  • Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
  • 06/25/2019

It's Time To Consider Leveraged Healthcare ETFs

  • With one of the industry's marquee conferences recently ending, traders may want to consider the Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) and the Direxion Daily S&P; Biotech Bull 3X Shares (NYSE: LABU). The American Society of Clinical Oncology Annual Meeting ended this week, which could bring CURE and LABU into focus for active traders.
  • 06/07/2019

5 Leveraged ETFs With Biggest 1-Month Fund Flows

  • For the past month, leveraged exchange-traded fund (ETF) traders have been feasting off opportunities in gold, biotech, large caps, and semiconductors as the U.S.-China trade deal went awry. The flight ...
  • 05/22/2019

7 ETFs for Investors With a Gambler’s Spirit

  • Exchange-traded funds (ETFs) are often aimed at conservative investors with long-term time horizons. Many of the largest ETFs on the market today are designed to provide cost-effective exposure to basic asset classes, such as domestic stocks, international equities and high-grade government bonds.Another selling point of a slew of ETFs to buy is that these funds feature broad lineups of stocks, a strategy that reduces concentration risk while eliminating the need for stock picking. Bottom line: may of the top ETFs to buy are inexpensive and easy to understand, selling points that were the foundation of the ETF industry two decades ago and traits that are likely to continue driving the industry's exponential growth.However, the ETF business is evolving and that evolution has led to the introductions of products aimed at more risk-tolerant traders and investors. Some of the better ETFs to buy for more adventurous investors include thematic funds while others are designed to be more tactical in nature.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Strong Buy Stocks That Tick All the Boxes Put it this way: if you're an investor with an adventurous spirit, there are plenty of ETFs to buy, but in many cases, that does not mean an investor should take on high levels of risk for extended periods of time. For investors looking to juice their returns or simply take on some added risk, here are some ETFs to buy. Best ETFs to Buy for Gamblers: ProShares UltraShort QQQ (QID)Expense Ratio: 0.95% per year, or $95 on a $10,000 investment.The ProShares UltraShort QQQ (NYSEARCA:QID) is designed to deliver double the daily inverse returns of the widely followed Nasdaq-100 Index, so if that index declines by 1% on a particular day, QID should rise by 2%.In other words, QID is a bad ETF to buy when the Nasdaq-100 is going up, something that tech-heavy benchmark has made a habit of doing over the course of the past decade. The current market environment clearly favors growth and technology stocks, two of the fortes of the Nasdaq-100, making QID an ETF to buy for contrarians or those looking to hedge long positions in Nasdaq-100 funds.In either case, investors should note QID and other leveraged ETFs are intended for short-term traders, not to be held for long holding periods, because the longer a leveraged ETF like QID is held, the more the chances increase that the fund will deviate from its stated objective.Interestingly, market participants have added nearly $181 million to QID this year. Global X MSCI Greece ETF (GREK)Expense Ratio: 0.59%The Global X MSCI Greece ETF (NYSEARCA:GREK) is the only U.S.-listed ETF dedicated to Greek equities. After years of being saddled by austerity measures and borrowing billions from the International Monetary Fund (IMF) and the European Union (EU), Greece is finally on the right fiscal path.GREK is up nearly 22% year-to-date, indicating investors view this as an ETF to buy."In Q1, the markets were up 15.2% and forecasts put 2019 GDP growth at annualized 2.4%, versus Europe at just 1.3%," said Global X in a recent research note. "Greece's improving growth prospects could portend the start of a virtuous cycle for Greece, making it a standout against the weak backdrop of a sluggish Europe." * 7 Energy Stocks to Buy to Light Up Your Portfolio What makes GREK a risky ETF to buy is, among other factors, a standard deviation of 24%, which is well above the comparable metric on emerging markets and Eurozone benchmarks. Those are relevant comparisons because Greece is a Eurozone member and classified as an emerging market. VanEck Vectors Junior Gold Miners ETF (GDXJ)Expense Ratio: 0.53%Among risky industry and sector ETFs to buy, mining funds are certainly part of that conversation and precious metals mining funds, such as the VanEck Vectors Junior Gold Miners ETF (NYSEARCA:GDXJ) are among the best ETFs to buy for risk-tolerant investors.GDXJ is a fine ETF to buy for an active, risk-aware trader looking to make a bet on rising gold prices. One of the risks, however, with gold mining ETFs is that the funds are not always responsive to higher bullion prices. Amplifying the risk profile is that when gold prices decline, shares of miners often overshoot spot gold's declines.Add all that into the wrapper of a small-cap fund and GDXJ is a volatile ETF to buy. The fund's standard deviation of more than 31% is well above that of basic gold funds and traditional small-cap ETFs. iPath Global Carbon ETN (GRN)Expense Ratio: 0.75%The iPath Global Carbon ETN (NYSEARCA:GRN) definitely is not a good ETF for all investors. This niche, lightly traded exchange-traded note (ETN) tracks the Barclays Global Carbon II TR USD Index.That index "is designed to measure the performance of the most liquid carbon-related credit plans. Each carbon-related credit plan included in the index is represented by the most liquid instrument available in the marketplace. The index expects to incorporate new carbon-related credit plans as they develop around the world," according to the issuer. * 10 Cheap Stocks to Buy Now While GRN has low correlations to traditional asset classes, the fund is not for conservative investors due to its history of high volatility. Not to mention, most investors can live without carbon credits in their portfolios. SPDR S&P; Oil & Gas Exploration & Production ETF (XOP)Expense Ratio: 0.35%For adventurous investors looking for energy sector exposure, the SPDR S&P; Oil & Gas Exploration & Production ETF (NYSEARCA:XOP) is one of the best ETFs to buy. XOP can be great when oil prices are trending higher because exploration and production stocks are typically more correlated to crude prices than integrated oil companies.XOP does come with the disclaimer that, as is the case throughout financial markets, there is no such thing as a free lunch. Compared to traditional energy funds that are heavily allocated to stocks like Exxon Mobil (NYSE:XOM) and Chevron (NYSE:CVX), XOP is significantly more volatile.The added volatility gets compounded when oil prices decline. When that happens, XOP and rival exploration and production ETFs often produce losses that far exceed those of basic energy ETFs. Direxion Daily S&P; Biotech Bull 3X Shares (LABU)Expense Ratio: 1.12%Like the aforementioned QID, the Direxion Daily S&P; Biotech Bull 3X Shares (NYSEARCA:LABU). In the case of LABU, this leveraged funds tries to deliver triple the daily returns of the S&P; Biotechnology Select Industry Index, so if that index rises by 1% on a particular day, LABU should jump by 3%.LABU is one of the best ETFs for risk tolerant because it amplifies the combination of biotechnology and volatility. Data confirm as much. Over the past month, LABU is one of Direxion's most volatile bullish leveraged ETFs, a status LABU frequently attains. * The 10 Best Stocks to Buy for May LABU is also one of the best ETFs for aggressive traders to deploy during biotechnology earnings season and around news events such as drug approvals and industry consolidation. What that means is traders should treat LABU like the short-term instrument it is. VanEck Vectors ChinaAMC SME-ChiNext ETF (CNXT)Expense Ratio: 0.65%Chinese small-caps probably are not the asset class for your retirement portfolio, but the VanEck Vectors ChinaAMC SME-ChiNext ETF (NYSEARCA:CNXT) is one of the best ETFs for investors seeking tactical exposure to the world's second-largest economy. CNXT fills some useful voids in international portfolios because many traditional China funds focus on large caps whereas this fund focuses on mid- and small-cap stocks.CNXT's underlying index "tracks the performance of the 100 largest and most liquid China A-share stocks listed and trading on the Small and Medium Enterprise ("SME") Board and the ChiNext Board of the Shenzhen Stock Exchange," according to VanEck.The weighted average market value of CNXT's 100 holdings is $12.8 billion, putting the fund just inside large-cap territory, but that number is still well below the average market caps found on holdings in traditional China ETFs.CNXT can be a bumpy ride. The fund is up 20% year-to-date, but that's after shedding 18% over the past month.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits Compare Brokers The post 7 ETFs for Investors With a Gambler's Spirit appeared first on InvestorPlace.
  • 05/07/2019

Weekly ETF Gainers / Losers (04/26/19)

  • No summary available.
  • 04/26/2019

Big Moves In Leveraged Biotech ETFs

  • Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action. What Happened Entering Monday, the Direxion Daily S&P; Biotech ...
  • 04/09/2019

Week 11 Breakout Forecast: Short-Term Picks To Give You An Edge

  • No summary available.
  • 03/11/2019

March: Exploiting Sector ETF Seasonality Patterns For Best Stock Gains

  • No summary available.
  • 03/07/2019
Unlock
LABU Ratings Summary
LABU Quant Ranking